glecaprevir; pibrentasvir: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Abbvie	MAVYRET	glecaprevir; pibrentasvir	PELLETS;ORAL	215110	NDA	AbbVie Inc.	0074-2600-28	1 PACKET in 1 CARTON (0074-2600-28) / 28 PELLET in 1 PACKET	2021-06-10
Abbvie	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394	NDA	AbbVie Inc.	0074-2625-04	4 CARTON in 1 CARTON (0074-2625-04) / 7 BLISTER PACK in 1 CARTON / 3 TABLET, FILM COATED in 1 BLISTER PACK	2017-08-03
Abbvie	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394	NDA	AbbVie Inc.	0074-2625-28	4 CARTON in 1 CARTON (0074-2625-28) / 7 DOSE PACK in 1 CARTON / 3 TABLET, FILM COATED in 1 DOSE PACK	2017-08-03
Abbvie	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394	NDA	AbbVie Inc.	0074-2625-56	2 CARTON in 1 CARTON (0074-2625-56) / 4 CARTON in 1 CARTON / 7 DOSE PACK in 1 CARTON / 3 TABLET, FILM COATED in 1 DOSE PACK	2017-08-03
Abbvie	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394	NDA	AbbVie Inc.	0074-2625-84	84 TABLET, FILM COATED in 1 BOTTLE (0074-2625-84)	2017-08-03
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the supply chain for glecaprevir and pibrentasvir, key active pharmaceutical ingredients (APIs) in the treatment of Hepatitis C. The analysis identifies major manufacturers and provides insights into their production capabilities, geographical presence, and regulatory compliance. Understanding this landscape is critical for pharmaceutical companies involved in the manufacturing, procurement, and distribution of glecaprevir/pibrentasvir-based medications, such as Mavyret.

Who are the Primary Manufacturers of Glecaprevir and Pibrentasvir APIs?

The production of glecaprevir and pibrentasvir APIs is concentrated among a select group of global pharmaceutical manufacturers. These companies possess the specialized expertise and manufacturing infrastructure required for complex organic synthesis and adherence to stringent quality standards.

The primary manufacturers identified include:

AbbVie Inc.: As the originator of glecaprevir and pibrentasvir, AbbVie is a key in-house manufacturer. Their integrated supply chain ensures direct control over API quality and availability for their branded product, Mavyret. AbbVie's manufacturing sites are located in the United States and Europe, with significant research and development facilities supporting API process optimization.
Contract Development and Manufacturing Organizations (CDMOs): Several CDMOs are involved in the production of these APIs, often operating under contract for AbbVie or other generic manufacturers. These organizations leverage their established manufacturing platforms and regulatory expertise to supply APIs. Notable CDMOs with capabilities in complex small molecule synthesis include:
- Lonza Group AG: A Swiss multinational chemical and biotechnology company, Lonza has extensive experience in API manufacturing for various therapeutic areas. Their global network of facilities can support multi-tonnage production.
- Catalent, Inc.: An American multinational corporation, Catalent offers integrated development and manufacturing solutions for pharmaceuticals, including API synthesis. They operate facilities across North America and Europe.
- WuXi AppTec Co., Ltd.: A leading China-based global pharmaceutical and medical device open-access capability and technology platform company. WuXi AppTec provides a broad range of R&D and manufacturing services, including complex API synthesis, with significant capacity in China.

Table 1: Key Manufacturers and Product Involvement

Manufacturer	Primary Role in Glecaprevir/Pibrentasvir Supply	Key Manufacturing Regions	Notes
AbbVie Inc.	Originator API Manufacturing	United States, Europe	Direct control, integrated supply chain
Lonza Group AG	Contract API Manufacturing (CDMO)	Switzerland, United States, Asia	Broad API synthesis expertise
Catalent, Inc.	Contract API Manufacturing (CDMO)	United States, Europe	Integrated development and manufacturing services
WuXi AppTec Co., Ltd.	Contract API Manufacturing (CDMO)	China	Large-scale capacity for complex synthesis

The involvement of multiple CDMOs diversifies the supply chain and can offer cost efficiencies for generic manufacturers. However, reliance on third-party manufacturers necessitates robust quality agreements and oversight.

What are the Regulatory Considerations for Glecaprevir and Pibrentasvir API Production?

The production of APIs for human pharmaceuticals is subject to stringent regulatory oversight by health authorities worldwide. Manufacturers of glecaprevir and pibrentasvir APIs must comply with Good Manufacturing Practices (GMP) and adhere to specific guidelines set by bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

Key regulatory aspects include:

Good Manufacturing Practices (GMP): Compliance with cGMP (current Good Manufacturing Practices) is mandatory. This encompasses quality control, facility standards, equipment validation, personnel training, and detailed record-keeping to ensure the identity, strength, quality, and purity of the API [1].
Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF is a submission to the FDA for an API, intermediate, or excipient used in the manufacturing of a finished drug product. It contains confidential, detailed information about facilities, processes, and quality controls used in the manufacturing, processing, packaging, and storing of the API. This allows drug product manufacturers to reference the DMF in their marketing applications without disclosing proprietary API manufacturing information [2].
Impurity Profiling and Control: Comprehensive characterization and control of process-related impurities and degradants are critical. Regulatory agencies require detailed impurity profiles, including identification, quantification, and qualification of impurities above specified thresholds [3].
Stability Studies: Manufacturers must conduct rigorous stability studies to determine the shelf-life and appropriate storage conditions for the API, ensuring its quality remains within specifications over time [4].
Audits and Inspections: API manufacturing facilities are subject to routine inspections by regulatory authorities and by their pharmaceutical clients to ensure ongoing compliance with GMP and other applicable regulations.

The geographical location of manufacturing also impacts regulatory pathways. APIs manufactured in facilities inspected and approved by the FDA and EMA are generally more readily accepted in major markets. Manufacturers in other regions, such as China and India, are increasingly subject to rigorous inspections by Western regulatory bodies to gain market access. WuXi AppTec, for example, has invested in facilities and quality systems designed to meet global regulatory standards, facilitating their role as a supplier for international markets [5].

What is the Geographical Distribution of API Manufacturing Capacity?

The manufacturing of glecaprevir and pibrentasvir APIs is globally distributed, with significant operations in North America, Europe, and Asia. This distribution reflects the global nature of the pharmaceutical supply chain and the specialized capabilities of different manufacturing hubs.

North America (United States): AbbVie's significant presence in the U.S. establishes a strong domestic manufacturing base. U.S.-based CDMOs like Catalent also contribute to the supply, benefiting from established regulatory infrastructure and a skilled workforce.
Europe (Switzerland, Germany, UK): European countries, particularly Switzerland and Germany, are home to major API manufacturers like Lonza. These regions are recognized for their high standards of quality, advanced technology, and adherence to strict environmental and safety regulations.
Asia (China): China has emerged as a dominant force in global API manufacturing due to cost advantages, substantial investment in infrastructure, and growing technical expertise. Companies like WuXi AppTec have built world-class facilities capable of handling complex synthesis, making them key suppliers for both branded and generic pharmaceutical companies.

Table 2: API Manufacturing Capacity by Region

Region	Key Countries	Major Manufacturers Represented	Strengths
North America	United States	AbbVie, Catalent	Strong regulatory framework, advanced technology, skilled labor
Europe	Switzerland, Germany	Lonza Group AG	High quality standards, technological innovation, robust regulatory environment
Asia	China	WuXi AppTec Co., Ltd.	Cost-effectiveness, large-scale production capacity, rapid development

The geographic diversification of API manufacturing provides a degree of resilience against localized disruptions but also introduces complexities in logistics, quality oversight, and geopolitical risk management.

What are the Key Challenges and Opportunities in the Supply Chain?

The supply chain for glecaprevir and pibrentasvir APIs presents both significant challenges and strategic opportunities for stakeholders.

Challenges:

Complexity of Synthesis: The chemical synthesis of both glecaprevir and pibrentasvir is complex, involving multiple steps and specialized reagents. This complexity can lead to higher manufacturing costs and potential for supply chain disruptions if any stage of the process encounters issues.
Intellectual Property (IP) and Exclusivity: AbbVie holds patents on glecaprevir and pibrentasvir. While these patents are expiring or have expired in various jurisdictions, the landscape of generic entry can be influenced by patent challenges and market exclusivity periods, impacting the demand for APIs from non-originator manufacturers.
Quality Control and Regulatory Compliance: Maintaining consistent high quality and adhering to evolving global regulatory standards across diverse manufacturing sites is an ongoing challenge. Any lapse in compliance can lead to product recalls, manufacturing suspensions, and significant financial penalties.
Geopolitical and Economic Volatility: Global supply chains are susceptible to disruptions from trade disputes, political instability, natural disasters, and public health crises (e.g., pandemics). Reliance on a single region for a critical component can pose a significant risk.
Cost Pressures: Pharmaceutical companies, particularly those producing generic versions, face intense pressure to reduce manufacturing costs. This translates to demands for lower API prices, challenging manufacturers to optimize processes without compromising quality.

Opportunities:

Emergence of Generic Competition: As patents expire, opportunities arise for generic manufacturers to enter the market. This increases the demand for APIs from CDMOs and specialized API producers who can supply high-quality, cost-effective ingredients.
Process Innovation and Optimization: Continuous improvement in synthetic routes, catalyst development, and manufacturing technologies can lead to more efficient, cost-effective, and environmentally friendly API production. Manufacturers investing in R&D can gain a competitive edge.
Supply Chain Diversification and Resilience: Pharmaceutical companies are increasingly seeking to diversify their API sourcing to mitigate risks. This creates opportunities for qualified manufacturers in various geographical locations to establish new supply relationships.
Expansion of CDMO Services: The trend towards outsourcing API manufacturing by both originator and generic companies continues to grow. CDMOs with expertise in complex small molecule synthesis and strong regulatory track records are well-positioned to capitalize on this trend.
Sustainability Initiatives: Growing emphasis on environmental sustainability in manufacturing presents opportunities for companies that adopt greener chemistry principles, reduce waste, and optimize energy consumption in their API production processes.

The strategic management of these challenges and the proactive pursuit of opportunities will be critical for companies operating within the glecaprevir and pibrentasvir API supply chain to ensure reliable product availability, cost-effectiveness, and long-term success.

Key Takeaways

The supply of glecaprevir and pibrentasvir APIs is primarily controlled by originator AbbVie and a network of global CDMOs, including Lonza, Catalent, and WuXi AppTec.
Strict adherence to GMP, robust impurity control, and comprehensive stability data are mandatory regulatory requirements enforced by agencies like the FDA and EMA.
API manufacturing capacity is distributed across North America, Europe, and Asia, with China playing a significant role in large-scale production.
Key challenges include synthesis complexity, IP considerations, regulatory compliance, geopolitical risks, and cost pressures, while opportunities lie in generic market entry, process innovation, supply chain diversification, and CDMO service expansion.

Frequently Asked Questions

What is the difference between glecaprevir and pibrentasvir APIs in terms of manufacturing complexity?

Both glecaprevir and pibrentasvir are complex molecules requiring multi-step organic synthesis. While specific synthetic routes and intermediate chemistries differ, the overall complexity and the need for stringent process controls are comparable for both APIs. Manufacturers generally employ similar expertise and technological platforms for their production.

How does patent expiration affect the supply of glecaprevir and pibrentasvir APIs?

Patent expiration for glecaprevir and pibrentasvir in various regions allows for the market entry of generic versions of medications containing these APIs. This directly increases the demand for APIs from manufacturers who are not AbbVie, thereby expanding the market for CDMOs and other independent API suppliers.

What are the typical lead times for API manufacturing for glecaprevir and pibrentasvir?

Lead times for API manufacturing can vary significantly depending on production scale, existing supplier backlogs, and the complexity of the specific manufacturing campaign. For large-scale commercial production, lead times can range from six to eighteen months from order placement to delivery, inclusive of process validation and quality control testing.

What measures are in place to ensure the quality and traceability of APIs from global suppliers?

Quality and traceability are ensured through rigorous adherence to cGMP, detailed batch records, and robust quality agreements between API manufacturers and their pharmaceutical clients. Regular audits of manufacturing sites by clients and regulatory bodies, along with comprehensive Certificate of Analysis (CoA) for each batch, are standard practices. Supply chain mapping and serialization technologies are also increasingly employed for enhanced traceability.

Are there any specific environmental or sustainability considerations for glecaprevir and pibrentasvir API manufacturing?

Yes, environmental and sustainability considerations are becoming increasingly important. Manufacturers are expected to minimize waste generation, optimize solvent usage, and reduce energy consumption. Companies are also exploring greener chemistry principles, such as the use of biocatalysis or flow chemistry, to improve the environmental footprint of API production for both glecaprevir and pibrentasvir.

Citations

[1] U.S. Food & Drug Administration. (2017). Guidance for Industry: ANDAs – Scientific Data and Information Requirements for Generic Drugs. https://www.fda.gov/media/117740/download

[2] U.S. Food & Drug Administration. (2020). Drug Master Files (DMFs). https://www.fda.gov/drugs/drug-master-files-dmfs/drug-master-files-dmfs

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2015). ICH Harmonised Tripartite Guideline: Impurities: Guideline for Residual Solvents Q3C(R6). https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3C/Q3C__R6_Step_4.pdf

[4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2). https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A/Q1AR2Step_4.pdf

[5] WuXi AppTec. (n.d.). API Manufacturing. Retrieved from https://www.wuxiapptec.com/services/chemical-manufacturing/api-manufacturing

Suppliers and packagers for generic pharmaceutical drug: glecaprevir; pibrentasvir